Articles tagged with: Drugs

BCI at the 60th ASH Annual Meeting

Posted in General News, BCI on the Road Published by Bethan Warman 14 January 2019

‘The premier event in malignant and non-malignant haematology’

BCI at the 60th ASH Annual Meeting

Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego on 1st-4th December 2018. The ASH Annual Meeting provides an invaluable opportunity to showcase the work being conducted here at the BCI and brings together professionals from all subspecialties of blood disease research.

Tackling the deadliest cancer type

Posted in General News Published by Bethan Warman 30 November 2018

Our lung cancer research

Tackling the deadliest cancer type

This month is Lung Cancer Awareness Month. Lung cancer is the third most common cancer in the UK, with 46,700 new cases diagnosed each year. Approximately 35,600 people lose their lives annually as a result of lung cancer in the UK, making it the most common cause of cancer-related mortality. Only 5% of those affected survive their cancer for 10 years or more in the UK, and this survival rate has not shown much improvement over the last four decades.

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Posted in General News, Publications Published by Bethan Warman 17 October 2018

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC). The phase 1 clinical trial, led by Prof Peter Schmid, Centre Lead for BCI’s Centre for Experimental Cancer Medicine, is the first to report the long-term safety and efficacy of the drug for mTNBC, and may represent significant steps forward for treatment of this disease.

Blood Cancer Awareness Month 2018

Posted in General News Published by Bethan Warman 28 September 2018

Blood Cancer Awareness Month 2018

Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year. The three main blood cancer types are leukaemia, lymphoma and myeloma; however, there are over 100 individual types.

World Cancer Research Day 2018

Posted in General News Published by Bethan Warman 24 September 2018

World Cancer Research Day 2018

Today is World Cancer Research Day- a day dedicated to raising awareness of the importance of cancer research. Thanks to a united effort by researchers from around the world, cancer survival rates have doubled in the last 40 years, and 50% of those diagnosed with cancer now survive. To continue to improve these statistics, it is vital to identify new and more effective early detection methods and treatments that can improve the lives of those with cancer.

Study links widely-used drug azathioprine to skin cancers

Posted in General News, Publications Published by Bethan Warman 14 September 2018

Study links widely-used drug azathioprine to skin cancers

A drug used to treat inflammatory bowel disease and arthritis, and prevent organ rejection in transplant patients, has been identified as an important contributor to skin cancer development in a study by researchers from Queen Mary University of London, including our Barts Cancer Research UK Centre (BCC) Bioinformatics team, the University of Dundee and the Wellcome Sanger Institute.

Pancreatic Cancer UK Grand Challenge

Posted in General News, Grants & Awards Published by Bethan Warman 27 July 2018

PCUK’s largest ever research fund

Pancreatic Cancer UK Grand Challenge

Our Director, Prof Nicholas Lemoine, and a team of researchers from the BCI and King’s College London have been awarded the Pancreatic Cancer UK (PCUK) Grand Challenge- PCUK’s largest ever research fund. The grant will be used for the development of a type of immunotherapy, known as CAR-T cell therapy, to treat pancreatic cancer.

Immunotherapy harnesses the body’s own immune system to identify and kill cancer cells, and has been demonstrated to be an effective treatment option in a variety of cancer types. In CAR-T cell therapy, T cells- key immune cells responsible for fighting infected cells- are isolated from patient blood samples, modified outside of the body and reinjected back into the patient. Once back in the body, the T cells are equipped to target and attack tumours.

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Posted in General News, Conferences, BCI on the Road Published by Bethan Warman 15 June 2018

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. The Centre Lead of our Centre for Experimental Cancer Medicine (CECM), Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles of the CECM and Director of the Barts Cancer Centre, presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.

International Clinical Trials Day 2018

Posted in General News Published by Bethan Warman 21 May 2018

International Clinical Trials Day 2018

International Clinical Trials Day is celebrated on 20th May each year in recognition of the clinical trials conducted around the world, which ensure that research from the laboratory can be translated into patient benefit. The progress that is continuing to be made in cancer research, resulting in cancer survival rates doubling in the last 40 years, would not be possible without the researchers, clinicians, nurses and, of course, patients that are involved in clinical trials each year.

[12  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.